肠道微生物组补充在COVID-19管理中的作用
Mc Anto Antony1, Siddharth Patel2, Vipin Verma3
1Department of Endocrinology, Diabetes and Metabolism, Medical University of South Carolina, Anderson, USA.
Cureus
|November 29, 2023
概括
本综述探讨了包括益生菌和益生菌在内的肠道保健补充剂如何帮助管理胃肠道症状,并可能预防与COVID-19 (冠状病毒病2019) 相关的严重后果. 需要进一步的研究来证实它们的有效性.
科学领域:
- 胃肠病学 胃肠病学
- 病毒学 病毒学
- 微生物组研究 微生物组研究
背景情况:
- 由SARS-CoV-2引起的COVID-19 (冠状病毒疾病2019),主要影响呼吸系统,但经常出现胃肠道 (GI) 症状.
- 在患者便中检测到SARS-CoV-2RNA,这表明胃肠道受影响,并可能导致长时间的便分泌.
- 住院COVID-19患者表现出显著的肠道微生物组失调,其特点是有益细菌减少和病原体增加.
研究的目的:
- 审查有关健康补充剂对减轻COVID-19临床表现的潜在益处的当前文献.
- 探索益生菌,益生菌,后生菌和共生菌在管理COVID-19患者的胃肠道症状和肠道失生症中的作用.
主要方法:
- 对现有的科学文献进行系统审查.
- 对调查肠道保健补充剂对COVID-19症状和结果的影响的研究分析.
- 对SARS-CoV-2及其对胃肠道系统和微生物群的影响的研究评估.
主要成果:
- COVID-19可以表现为各种胃肠道症状,病毒可以在便样本中持续存在.
- 在COVID-19患者中观察到肠道微生物组的显著变化.
- 益生菌,益生菌,后生菌和共生菌等保健补充剂在解决这些胃肠道和微生物群干扰方面表现有前途.
结论:
- 肠道保健补充剂可能为管理COVID-19,特别是其胃肠道表现提供一种新的治疗途径.
- 这些补充剂可能有助于恢复因SARS-CoV-2感染而破坏的肠道微生物组平衡.
- 需要进一步进行临床研究,以确定这些干预措施在预防或治疗COVID-19中的有效性.
相关概念视频
What is Monogastric Digestion?
71.2K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
71.2K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
335
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
335
Factors Affecting the Risk of Infection
11.8K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
11.8K
Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
Cystic Fibrosis: Management
172
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
172
Acute Respiratory Failure-V
142
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
142


